Ritual Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 02-01-2025
- Paid Up Capital ₹ 2.50 M
as on 02-01-2025
- Company Age 3 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.75 Cr
as on 02-01-2025
- Revenue 1336.70%
(FY 2023)
- Profit -189.24%
(FY 2023)
- Ebitda -90.73%
(FY 2023)
- Net Worth -471.13%
(FY 2023)
- Total Assets 49.28%
(FY 2023)
About Ritual Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹3.75 Cr.
Rakesh Kumar, Pardeep, Nitin Kumar, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299HR2021PTC093681
- Company No.
093681
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Mar 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Sonipat, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Ritual Drugs Private Limited offer?
Ritual Drugs Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Common Disease Medicines, Antihistamines, Vitamin Tablets & Capsules, Muscle Relaxant, Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing.
Who are the key members and board of directors at Ritual Drugs?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Kumar  | Director | 27-Jun-2023 | Current |
| Pardeep | Director | 24-Aug-2023 | Current |
| Nitin Kumar | Director | 22-Aug-2023 | Current |
| Nand Singh | Director | 29-Dec-2023 | Current |
Financial Performance of Ritual Drugs.
Ritual Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1336.7% increase. The company also saw a substantial fall in profitability, with a 189.24% decrease in profit. The company's net worth observed a substantial decline by a decrease of 471.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ritual Drugs?
In 2023, Ritual Drugs had a public holding of 77.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Jul 2022 | ₹5.00 M | Open |
Others Creation Date: 18 Jun 2021 | ₹3.25 Cr | Open |
How Many Employees Work at Ritual Drugs?
Ritual Drugs has a workforce of 13 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ritual Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ritual Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
